Der Onkologe

, Volume 12, Issue 10, pp 1003–1011 | Cite as

Diagnostik und Therapie der akuten myeloischen Leukämie des Erwachsenen



Das Verständnis der Biologie der akuten myeloischen Leukämie (AML) hat sich in den letzten Jahren deutlich verbessert. Dies macht den Einsatz komplexer diagnostischer Verfahren und die Einführung neuer Klassifikationssysteme notwendig. Gleichzeitig ergeben sich Möglichkeiten für risikoadaptierte bzw. subgruppenspezifische Therapiestrategien. Neue Prognosefaktoren und Therapieverfahren führen zu einer nicht unerheblichen Verunsicherung bei der Behandlung der AML im klinischen Alltag. Der vorliegende Beitrag gibt deshalb eine Übersicht über moderne Diagnoseverfahren, neue Prognosefaktoren und die aktuelle prognostische Einteilung der AML. Weiterhin werden die etablierten Therapiestrategien dargestellt und im Kontext der aktuellen Literatur bewertet. Zuletzt werden neue Therapieansätze und deren Perspektiven aufgezeigt.


Akute myeloische Leukämie Erwachsene Diagnostik Therapie Prognostische Faktoren 

Diagnostic work-up and treatment of acute myeloid leukemia in adults


In recent years knowledge about the biology of acute myeloid leukemia has improved tremendously. This has led to the necessity of using complex diagnostic procedures and introducing new classification systems. In parallel possibilities evolved for risk-adapted or specific therapeutic strategies within subgroups of the disease. New prognostic factors and therapeutic options led to significant confusion regarding the day-to-day routine in AML therapy. The report presented here gives an overview of modern diagnostic procedures, new prognostic factors, and up-to-date prognostic classification systems in AML. Furthermore, established therapeutic strategies are described and discussed in the context of the most recent literature. Finally, new therapeutic possibilities and their perspectives for the future are highlighted.


Acute myeloid leukemia Adults Diagnostics Therapy Prognostic factors 


  1. 1.
    Appelbaum FR, Gundacker HM, Head DR et al. (2006) Age and acute myeloid leukemia. Blood 107: 3481–3485CrossRefPubMedGoogle Scholar
  2. 2.
    Baer MR (2002) Detection of minimal residual disease in acute myeloid leukemia. Curr Oncol Rep 4: 398–402PubMedGoogle Scholar
  3. 3.
    Bene MC, Bernier M, Casasnovas RO et al. (1998) The reliability and specificity of c-kit for the diagnosis of acute myeloid leukemias and undifferentiated leukemias. The European Group for the Immunological Classification of Leukemias (EGIL). Blood 92: 596–599PubMedGoogle Scholar
  4. 4.
    Bennett JM, Catovsky D, Daniel MT et al. (1976) Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 33: 451–458PubMedGoogle Scholar
  5. 5.
    Bernasconi P, Boni M, Cavigliano PM et al. (2002) Molecular genetics of acute myeloid leukemia. Ann N Y Acad Sci 963: 297–305PubMedGoogle Scholar
  6. 6.
    Bertz H, Potthoff K, Finke J (2003) Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 21: 1480–1484CrossRefPubMedGoogle Scholar
  7. 7.
    Bradstock KF, Matthews JP, Lowenthal RM et al. (2005) A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine. Blood 105: 481–488CrossRefPubMedGoogle Scholar
  8. 8.
    Buchner T, Dohner H, Ehninger G et al. (2002) Up-front randomization and common standard arm: a proposal for comparing AML treatment strategies between different studies. Leuk Res 26: 1073–1075CrossRefPubMedGoogle Scholar
  9. 9.
    Buchner T, Hiddemann W, Berdel WE et al. (2003) 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. J Clin Oncol 21: 4496–4504CrossRefPubMedGoogle Scholar
  10. 10.
    Buchner T, Hiddemann W, Wormann B et al. (1999) Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 93: 4116–4124PubMedGoogle Scholar
  11. 11.
    Burnett AK, Wheatley K, Goldstone AH et al. (2002) The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 118: 385–400CrossRefPubMedGoogle Scholar
  12. 12.
    Byrd JC, Mrozek K, Dodge RK et al. (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100: 4325–4336CrossRefPubMedGoogle Scholar
  13. 13.
    Cheson BD, Bennett JM, Kopecky KJ et al. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 21: 4642–4649CrossRefPubMedGoogle Scholar
  14. 14.
    Estey EH (2000) How I treat older patients with AML. Blood 96: 1670–1673PubMedGoogle Scholar
  15. 15.
    Gerrard G, Payne E, Baker RJ et al. (2004) Clinical effects and P-glycoprotein inhibition in patients with acute myeloid leukemia treated with zosuquidar trihydrochloride, daunorubicin and cytarabine. Haematologica 89: 782–790PubMedGoogle Scholar
  16. 16.
    Harris NL, Jaffe ES, Diebold J et al. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17: 3835–3849PubMedGoogle Scholar
  17. 17.
    Hellenbrecht A, Messerer N, Gokbuget N (2003) Häufigkeit von Leukämien bei Erwachsenen in Deutschland.
  18. 18.
    Larson RA, Sievers EL, Stadtmauer EA et al. (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 104: 1442–1452CrossRefPubMedGoogle Scholar
  19. 19.
    Leone G, Mele L, Pulsoni A et al. (1999) The incidence of secondary leukemias. Haematologica 84: 937–945PubMedGoogle Scholar
  20. 20.
    Mayer RJ, Davis RB, Schiffer CA et al. (1994) Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 331: 896–903CrossRefPubMedGoogle Scholar
  21. 21.
    Moore JO, George SL, Dodge RK et al. (2005) Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood 105: 3420–3427CrossRefPubMedGoogle Scholar
  22. 22.
    Nathan PC, Sung L, Crump M et al. (2004) Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis. J Natl Cancer Inst 96: 38–45Google Scholar
  23. 23.
    Platzbecker U, Thiede C, Fussel M et al. (2006) Reduced intensity conditioning allows for up-front allogeneic hematopoietic stem cell transplantation after cytoreductive induction therapy in newly-diagnosed high-risk acute myeloid leukemia. Leukemia 20: 707–714CrossRefPubMedGoogle Scholar
  24. 24.
    Pulsoni A, Pagano L, Latagliata R et al. (2004) Survival of elderly patients with acute myeloid leukemia. Haematologica 89: 296–302PubMedGoogle Scholar
  25. 25.
    Sanz MA, Martin G, Gonzalez M et al. (2004) Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood 103: 1237–1243CrossRefPubMedGoogle Scholar
  26. 26.
    Schaich M, Soucek S, Thiede C et al. (2005) MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 128: 324–332CrossRefPubMedGoogle Scholar
  27. 27.
    Stone RM, DeAngelo DJ, Klimek V et al. (2005) Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105: 54–60CrossRefPubMedGoogle Scholar
  28. 28.
    Suciu S, Mandelli F, de Witte T et al. (2003) Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood 102: 1232–1240CrossRefPubMedGoogle Scholar
  29. 29.
    Thiede C, Koch S, Creutzig E et al. (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107: 4011–4020CrossRefPubMedGoogle Scholar
  30. 30.
    Thiede C, Steudel C, Mohr B et al. (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99: 4326–4335CrossRefPubMedGoogle Scholar

Copyright information

© Springer Medizin Verlag 2006

Authors and Affiliations

  1. 1.Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav CarusDresdenDeutschland

Personalised recommendations